Lv4
528 积分 2022-08-02 加入
When to adjust for multiplicity in cancer clinical trials
15小时前
待确认
Addressing missing outcome data in randomised controlled trials: A methodological scoping review
15小时前
待确认
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
15小时前
已完结
The promises and challenges of neoantigen cancer vaccines
15小时前
已完结
Capturing and Tracking Clonal T-cell Response to Cancer Neoantigens
15小时前
已完结
Transparent Reporting of Observational Studies Emulating a Target Trial—The TARGET Statement
15小时前
已完结
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
15小时前
已完结
Important Considerations for ELISpot Validation
15小时前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
15小时前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
15小时前
已完结
皖公网安备34019202002308
